Clinical Trials Browser

Phase 2/3 × Capecitabine × 90 days × Clear all

NCT06926868 2026-03-11

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07413939 2026-03-10

BREnnA

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT07309419 2025-12-30

Cocktail-001

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular